Recent news highlights Cingulate's FDA regulatory challenges with its ADHD drug CTx-1301, ongoing efforts to address manufacturing deficiencies, and analyst coverage maintaining buy recommendations.

• In June 2026, Cingulate received a Complete Response Letter from the FDA for its ADHD drug CTx-1301 citing Chemistry, Manufacturing and Controls (CMC) information requests; the company is working on remediation with its CDMO [N5][N4].
• Despite the CRL, Cingulate's stock showed gains and was noted among top biotech gainers in early June 2026 [N3][N2].
• Analyst firms Ascendiant Capital and Roth Capital maintained buy recommendations on Cingulate in late 2025 [N7][N8].
• The company completed key Phase 3 safety trials for CTx-1301 and submitted its NDA in July 2025, with FDA acceptance in October 2025 [N6].
• Cingulate's stock activity and news flow reflect ongoing investor interest amid regulatory developments [N1].

Cingulate has advanced its lead ADHD drug candidate CTx-1301 to late-stage development and submitted an NDA accepted by the FDA. The proprietary drug delivery platform and flexible core tableting technology may offer clinical and commercial advantages. The company has demonstrated ability to raise capital and maintain liquidity to support ongoing development. Positive clinical data and successful resolution of manufacturing issues could enable regulatory approval and market entry, supporting business growth.

The company has not generated revenues and has incurred substantial net losses and accumulated deficits. The FDA issued a Complete Response Letter citing manufacturing deficiencies for CTx-1301, which may delay or prevent approval. Reliance on a single CDMO for manufacturing poses supply chain and regulatory risks. Additional capital will be required to fund operations and development. Failure to obtain regulatory approval or to commercialize products would materially harm the business and financial condition.

Cingulate's moat is based on its proprietary drug delivery platform technology enabling once-daily tablets of multi-dose therapies, targeting ADHD and anxiety markets. The company’s focus on flexible core tableting technology designed for rapid onset and controlled plasma drug levels may provide differentiation. However, as a clinical-stage company without approved products, its moat is contingent on successful regulatory approval and commercialization. The reliance on a single CDMO for manufacturing introduces operational risks that could affect competitive positioning.

• Regulatory Approval Risk: The FDA issued a Complete Response Letter for CTx-1301 citing manufacturing deficiencies, which may delay or prevent approval. The FDA may conduct re-inspections and identify additional issues.
• Manufacturing and Supply Chain Risk: The company relies on a single CDMO, Bend Bioscience, for manufacturing. Any failure to meet cGMP standards or supply disruptions could delay clinical trials, regulatory submissions, or commercialization.
• Financial Risk: Cingulate has incurred significant losses and has an accumulated deficit. It requires additional capital to fund operations and development, with no assurance of availability on acceptable terms.
• Commercialization Risk: The company has no approved products and limited commercial experience. Successful commercialization depends on regulatory approval and market acceptance.

• Cingulate Inc. is a biopharmaceutical company focused on developing proprietary stimulant medications for ADHD and anxiety using a drug delivery platform technology enabling once-daily tablets of multi-dose therapies [S1].
• The lead product candidate is CTx-1301 (dexmethylphenidate), in late-stage development, with a New Drug Application (NDA) submitted to the FDA in July 2025 and a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026 [S1].
• The company also develops CTx-1302 (dextroamphetamine) for ADHD and CTx-2103 for anxiety, with CTx-1302 clinical plans pending additional capital [S1].
• In June 2026, Cingulate received a Complete Response Letter (CRL) from the FDA for CTx-1301 citing Chemistry, Manufacturing and Controls (CMC) deficiencies but no clinical safety or efficacy concerns; the company is generating additional data and working with its contract development and manufacturing organization (CDMO), Bend Bioscience, to address these issues [S2].
• The CDMO's manufacturing facility received a Form 483 with three observations during a February 2026 FDA pre-approval inspection; remediation efforts are ongoing [S2].
• The company relies heavily on Bend Bioscience as a single-source CDMO for manufacturing, which poses risks related to supply chain, regulatory compliance, and potential delays if issues are not resolved [S2].
• Cingulate has not generated revenues and has incurred net losses since inception, with an accumulated deficit of approximately $132.4 million as of December 31, 2025 [S1].
• The company reported a net loss of $5.87 million and basic and diluted EPS of -$0.45 for the quarter ended June 30, 2026 [S2].
• As of June 30, 2026, Cingulate had cash and cash equivalents of approximately $28.4 million and a current ratio of 3.5, indicating liquidity to support near-term operations [S2].
• The company has a lease for its Kansas City headquarters with a five-year term starting June 1, 2025, with monthly rent of $33,145 [S1].
• Management and board members have extensive experience in pharmaceutical development, commercialization, finance, and legal compliance [S1].
• The company depends heavily on the successful development, regulatory approval, and commercialization of CTx-1301; failure or delay in approval could materially affect its business and financial condition [S2].
• The company has licensing agreements requiring milestone payments upon clinical and regulatory milestones, including a $250,000 payment upon FDA approval of CTx-1301 [S1].
• Cingulate has raised capital through various equity offerings, private placements, and convertible notes to fund operations and development [S1].
• The company operates as a single operating segment focused on research, development, and manufacturing of its product candidates [S1].
• The company’s internal controls over financial reporting were evaluated as effective as of December 31, 2025 [S1].